Related Experiment Videos
Use of esmolol in the postbypass management of hypertrophic obstructive cardiomyopathy
L G Ooi1, P J O'Shea, A J Wood
1Department of Anaesthesia, Royal London Hospital, Whitechapel.
Insights
Beta-blockers can improve hypertrophic obstructive cardiomyopathy (HOCM) during anesthesia. Esmolol, an ultra-short-acting beta-blocker, was successfully used in perioperative management for surgical correction of HOCM.
Area of Science:
- Cardiology
- Anesthesiology
- Pharmacology
Background:
- Hypertrophic obstructive cardiomyopathy (HOCM) presents risks during anesthesia due to potential catecholamine release.
- Catecholamine surges can worsen outflow tract obstruction and reduce cardiac output in HOCM patients.
Observation:
- Esmolol, an ultra-short-acting beta-blocker with a 9-minute half-life, was considered for managing HOCM during anesthesia.
- The study details the perioperative use of esmolol in a patient undergoing surgical correction for HOCM.
Findings:
- Esmolol effectively managed the patient's condition during the perioperative period.
- The ultra-short-acting nature of esmolol makes it suitable for rapid titration and management of hemodynamic changes.
Implications:
- Esmolol offers a valuable therapeutic option for perioperative management in HOCM patients.
- This case highlights the potential benefits of targeted beta-blockade in mitigating anesthetic risks associated with HOCM.
Abstract:
In patients suffering from hypertrophic obstructive cardiomyopathy (HOCM), any catecholamine release during anaesthesia may aggravate the severity of the outflow tract obstruction and compromise cardiac output. In this event the situation may be improved by beta block. Esmolol, an ultra-short-acting beta-blocker (half-life 9 min) appears to be a suitable agent for this purpose. We describe its use in the perioperative management of a patient who underwent surgical correction of HOCM.